Glioma is a cancer of the brain that begins in glial cells (cells that surround and support nerve cells).
Researchers at the Francis Crick Institute have identified a protein that helps tumors evade the immune system and, in certain types of cancers, is linked to a poorer chance of survival. The protein could become a target for future cancer treatments.
Brain tumor cells with a certain common mutation reprogram invading immune cells. This leads to the paralysis of the body's immune defense against the tumor in the brain. Researchers from Heidelberg, Mannheim, and Freiburg discovered this mechanism and at the same time identified a way of reactivating the paralyzed immune system to fight the tumor.
Scientists have largely been producing transcriptomic data in an attempt to find clues about modified cellular pathways that may be fueling cancer behavior.
For many cancers, doctors are increasingly looking to the DNA that solid tumors shed into the blood stream to help with diagnosis and monitoring.
The evolution of the refined human immune system has turned into an effective defense system against several diseases, including cancer.
A new bioluminescent reporter that tracks DNA double stranded break (DSB) repair in cells has been developed by researchers from Massachusetts General Hospital (MGH) and the Academia Sinica in Taiwan.
New insight into a gene that controls energy production in cancer stem cells could help in the search for a more effective treatment for glioblastoma.
Every year, 150 to 300 children in the United States are diagnosed with diffuse intrinsic pontine gliomas (DIPGs), aggressive and lethal tumors that grow deep inside the brain, for which there are no cures.
Far Eastern Federal University (FEFU) scientists have developed implantable hydrogels based on plant polysaccharides (pectins). They can play the role of an artificial extracellular matrix, a special network of molecules that fills the space between body cells.
Therapies for treating glioblastoma brain cancer can be delivered with greater precision and existing drugs can be used in new ways.
Researchers from IRB Barcelona, the University of Barcelona (UB) and the Sant Joan de Déu Research Institute - Hospital Sant Joan de Déu (SJD) have set up Gate2Brain, a company based on a novel technology developed at IRB Barcelona to transport drugs into the brain.